Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography

JAMA

Volumn 296, Issue 21, 2006, Pages 2590-2600

  Veit Haibach, Patrick ^a   Kuehle, Christiane A ^a   Beyer, Thomas ^a   Stergar, Hrvoje ^a   Kuehl, Hilmar ^a   Schmidt, Johannes ^b   Börsch, Gereon ^c   Dahmen, Gerlinde ^d   Barkhausen, Joerg ^a   Bockisch, Andreas ^a   Antoch, Gerald ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Catholic Hospital Essen   (Germany)

^c ELISABETH KRANKENHAUS ESSEN   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 33845400192     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.21.2590     Document Type: Article

References (45)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005;365:305-311.
3. Stevenson GW. Colorectal cancer imaging: a challenge for radiologists. Radiology. 2000;214:615-621.
4. Filippone A, Ambrosini R, Fuschi M, Marinelli T, Genovesi D, Bonomo L. Preoperative T and N staging of colorectal cancer: accuracy of contrast-enhanced multi-detector row CT colonography - initial experience. Radiology. 2004;231:83-90.
5. Saunders TH, Mendes Ribeiro HK, Gleeson FV. New techniques for imaging colorectal cancer: the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up. Br Med Bull. 2002;64:81-99.
6. European Society for Medical Oncology Web site. http://www.esmo.org. Accessibility verified October 24, 2006.
7. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessibility verified October 24, 2006.
8. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med. 2005;142:635-650.
9. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging - a meta-analysis. Radiology. 2004;232:773-778.
10. Sosna J, Morrin MM, Kruskal JB, Farrell RJ, Nasser I, Raptopoulos V. Colorectal neoplasms: role of intravenous contrast-enhanced CT colonography. Radiology. 2003;228:152-156.
11. Sosna J, Kruskal JB, Bar-Ziv J, Copel L, Sella T. Extracolonic findings at CT colonography. Abdom Imaging. 2005;30:709-713.
12. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
13. Kantorova I, Lipska L, Belohlavek O, et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784-1788.
14. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511.
15. Kalff V, Hicks RJ, Ware RE, et al. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492-499.
16. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998;206:755-760.
17. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177-1189.
18. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797-1803.
19. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1210.
20. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027-1034.
21. Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging. 2004;29:663-668.
22. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357-4368.
23. Kim JH, Czernin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005;46:587-595.
24. Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46:758-762.
25. Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol. 2005;185:495-500.
26. Veit P, Kuehle C, Beyer T, et al. Whole-body PET/CT tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut. 2006;55:68-73.
27. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology. 2004;230:879-885.
28. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588-596.
29. Taylor SA, Halligan S, Goh V, et al. Optimizing colonic distention for multi-detector row CT colonography: effect of hyoscine butylbromide and rectal balloon catheter. Radiology. 2003;229:99-108.
30. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510-515.
31. Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology. 1991;180:319-322.
32. Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography. Radiology. 1995;194:349-352.
33. Zhou X-H, Obuchowski NA, McClish DK. Comparing the accuracy of two diagnostic tests. In: Statistical Methods in Diagnostic Medicine. New York, NY: Wiley; 2002:165-194.
34. Tango T. Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med. 1998;17:891-908.
35. Nakamoto Y, Chin BB, Cohade C, Osman M, Tatsumi M, Wahl RL. PET/CT: artifacts caused by bowel motion. Nucl Med Commun. 2004;25:221-225.
36. Yamamoto M, Mine H, Kusumoto H, Maehara Y, Sugimachi K. Polyps with different grades of dysplasia and their distribution in the colorectum. Hepatogastroenterology. 2004;51:121-123.
37. DiSario JA, Foutch PG, Mai HD, Pardy K, Manne RK. Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. Am J Gastroenterol. 1991;86:941-945.
38. Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001;42:989-992.
39. Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med. 2001;28:1766-1769.
40. Friedland S, Soetikno R, Carlisle M, Taur A, Kaltenbach T, Segall G. 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrointest Endosc. 2005;61:395-400.
41. Hara AK, Johnson CD, MacCarty RL, Welch TJ, McCollough CH, Harmsen WS. CT colonography: single- versus multi-detector row imaging. Radiology. 2001;219:461-465.
42. Wyss MT, Honer M, Schubiger PA, Ametamey SM. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging. 2006;33:311-318.
43. Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging. 2005;32:764-770.
44. Mahy P, De Bast M, Leveque PH, et al. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl) acetamide, [(18)F]EF3. Eur J Nucl Med Mol Imaging. 2004;31:1263-1272.
45. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106-113.